STTK

Shattuck Labs, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.84
52-Week Range: $1.70 – $8.33
Market Cap: $675.44M
P/E (TTM): —
EPS (TTM): -0.47
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.21
PEG Ratio: —
Return on Equity: -39.21%
Return on Assets: -24.43%
Gross Margin: 0.00%
Operating Margin: -5570.50%
Profit Margin: 0.00%
Current Ratio: 27.59
Debt/Equity: 0.01
Total Debt: $2.67M
Free Cash Flow: $-21.22M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $469.82M

STTK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$652.00K	$1.66M	$5.72M	$1.00M
Research & Development	$82.90M	$74.31M	$67.21M	$35.27M
Selling, General & Admin	$21.08M	$19.30M	$19.08M	$17.23M
Operating Expenses	$103.98M	$93.61M	$86.29M	$52.51M
Operating Income	-$103.33M	-$91.96M	-$80.57M	-$51.51M
EBITDA	-$100.26M	-$87.92M	-$76.74M	-$47.82M
Pretax Income	-$101.94M	-$87.30M	-$75.41M	-$48.81M
Net Income	-$101.94M	-$87.30M	-$75.41M	-$48.81M
Diluted EPS	-2.41	-2.05	-1.49	-0.70
Diluted Shares	42.38M	42.60M	50.76M	69.58M

STTK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$47.38M	$125.63M	$57.39M	$54.19M
Current Assets	$184.58M	$143.22M	$79.22M	$82.47M
Total Assets	$205.32M	$159.56M	$91.05M	$91.03M
Current Liabilities	$24.96M	$11.45M	$8.92M	$7.05M
Total Debt	$4.90M	$4.20M	$3.41M	$2.42M
Total Liabilities	$29.17M	$14.86M	$11.42M	$8.64M
Retained Earnings	-$219.01M	-$306.31M	-$381.72M	-$430.53M
Shareholders' Equity	$176.16M	$144.71M	$79.63M	$82.39M
Working Capital	$159.62M	$131.77M	$70.30M	$75.42M

STTK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$94.50M	-$81.23M	-$60.52M	-$39.88M
Capital Expenditure	-$11.61M	-$407.00K	-$59.00K	-$71.00K
Free Cash Flow	-$106.11M	-$81.64M	-$60.57M	-$39.95M
Depreciation & Amortisation	$3.07M	$4.04M	$3.83M	$3.69M
Stock-Based Compensation	$6.46M	$6.94M	$9.55M	$7.00M
Investing Cash Flow	$49.44M	$110.86M	-$8.51M	-$7.89M
Financing Cash Flow	$171.00K	$48.62M	$787.00K	$44.57M
Share Repurchases	—	—	-$17.00K	—
Net Change in Cash	-$44.89M	$78.25M	-$68.24M	-$3.19M

STTK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$1.00M	$0.00	$0.00	$0.00
Research & Development	$9.92M	$8.68M	$7.62M	$9.05M	$10.95M	$11.70M
Selling, General & Admin	$4.47M	$4.35M	$4.10M	$4.32M	$4.60M	$4.46M
Operating Expenses	$14.39M	$13.03M	$11.72M	$13.37M	$15.54M	$16.16M
Operating Income	-$14.39M	-$13.03M	-$10.72M	-$13.37M	-$15.54M	-$16.16M
EBITDA	-$13.45M	-$12.10M	-$9.80M	-$12.46M	-$14.65M	-$15.30M
Pretax Income	-$13.70M	-$12.46M	-$10.06M	-$12.59M	-$14.77M	-$15.15M
Net Income	-$13.70M	-$12.46M	-$10.06M	-$12.59M	-$14.77M	-$15.15M
Diluted EPS	-0.27	-0.24	-0.14	-0.12	-0.13	-0.12
Diluted Shares	50.97M	51.00M	72.18M	103.78M	112.23M	129.78M

STTK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$60.90M	$50.47M	$42.55M	$54.19M	$90.42M	$63.30M
Current Assets	$66.40M	$54.67M	$90.72M	$82.47M	$93.75M	$213.27M
Total Assets	$77.17M	$64.37M	$100.33M	$91.03M	$102.12M	$220.67M
Current Liabilities	$7.32M	$5.34M	$5.34M	$7.05M	$4.25M	$7.73M
Total Debt	$3.19M	$2.97M	$2.63M	$2.42M	$2.89M	$2.67M
Total Liabilities	$9.58M	$7.35M	$7.09M	$8.64M	$6.29M	$9.53M
Retained Earnings	-$395.42M	-$407.88M	-$417.94M	-$430.53M	-$445.30M	-$460.45M
Shareholders' Equity	$67.59M	$57.02M	$93.24M	$82.39M	$95.83M	$211.14M
Working Capital	$59.09M	$49.34M	$85.39M	$75.42M	$89.50M	$205.54M

STTK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$12.03M	-$10.43M	-$8.93M	-$8.49M	-$13.42M	-$10.19M
Free Cash Flow	-$12.03M	-$10.43M	-$9.00M	-$8.49M	-$13.42M	-$10.33M
Depreciation & Amortisation	$936.00K	$929.00K	$917.00K	$906.00K	$891.00K	$851.00K
Stock-Based Compensation	$1.72M	$1.89M	$1.78M	$1.61M	$2.42M	$2.73M
Investing Cash Flow	$15.60M	$0.00	-$43.49M	$20.00M	$23.85M	-$144.95M
Financing Cash Flow	-$57.00K	$0.00	$44.50M	$134.00K	$25.80M	$128.01M
Net Change in Cash	$3.51M	-$10.43M	-$7.92M	$11.64M	$36.23M	-$27.12M

Market Snapshot

About

Shattuck Labs is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine. The company focuses on cancer immunotherapy, designing molecules that simultaneously inhibit checkpoint pathways and stimulate immune responses. Their proprietary Agonist Redirected Checkpoint platform aims to overcome limitations of traditional cancer treatments.